Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price shot up 4.5% during trading on Monday . The company traded as high as $5.22 and last traded at $5.26. 7,894,043 shares were traded during mid-day trading, a decline of 67% from the average session volume of 24,109,020 shares. The stock had previously closed at $5.03.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. Needham & Company LLC lowered their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a report on Monday, June 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $7.00.
Get Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Stock Up 2.2%
The company has a market cap of $2.13 billion, a P/E ratio of -2.97 and a beta of 0.91. The stock has a 50-day moving average of $4.87 and a 200 day moving average of $6.14. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The business had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned ($0.39) earnings per share. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock worth $137,000 after acquiring an additional 6,699 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Recursion Pharmaceuticals by 7.6% during the fourth quarter. Rhumbline Advisers now owns 334,032 shares of the company's stock valued at $2,258,000 after purchasing an additional 23,564 shares in the last quarter. Private Advisor Group LLC increased its stake in shares of Recursion Pharmaceuticals by 103.8% in the fourth quarter. Private Advisor Group LLC now owns 31,427 shares of the company's stock valued at $212,000 after buying an additional 16,008 shares during the period. IFP Advisors Inc raised its holdings in Recursion Pharmaceuticals by 170.4% in the 4th quarter. IFP Advisors Inc now owns 11,831 shares of the company's stock valued at $80,000 after buying an additional 7,455 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $163,000. Institutional investors own 89.06% of the company's stock.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
